Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Core Viewpoint - Beta Bionics, Inc. is set to announce its fourth quarter and full year 2025 financial results on February 17, 2026, after market close, followed by a conference call to discuss performance [1]. Company Overview - Beta Bionics, Inc. is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes, utilizing advanced adaptive closed-loop algorithms [3]. - The company's flagship product, the iLet Bionic Pancreas, is the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a broad population of people with diabetes [3]. Investor Relations - For investor inquiries, Blake Beber serves as the Head of Investor Relations, and can be contacted via email [4]. - Media and public relations are managed by Karen Hynes, Vice President of Marketing, who is also available for contact [4]. Event Details - The conference call and webcast will take place at 4:30 PM Eastern Time (1:30 PM Pacific Time) on February 17, 2026, to review the company's financial performance [1]. - A link to the webcast will be available on the company's website and will be archived for future access [2].